CTI acquires tosedostat rights from Vernalis and Chroma

27 October 2014

Blood-related cancer specialist CTI BioPharma (Nasdaq: CTIC) has acquired the worldwide rights to tosedostat through transactions with its originator, the UK's Vernalis (LSE: VER), and Chroma, through which CTI previously held a sublicense with respect to tosedostat in North, Central and South America.

It is a selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival. Tosedostat is currently being evaluated in multiple Phase II clinical trials for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome, which are intended to inform the design of a Phase III registration study to support potential regulatory approval.

Terms of the CTI-Chroma agreement

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK